Clinical Trials
We are dedicated to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer.
This goal is accomplished through clinical trials.
A clinical trial is an experimental study that tests the effects of a new agent (vaccine or drug) in patients with cancer.
Most tumor immunotherapy treatments are currently only available through clinical trials.
At Columbia, we conduct early Phase I studies of new agents through the National Cancer Institute, as well as Phase II and III clinical trials supported by pharmaceutical companies and the Southwest Oncology Group (SWOG), a national consortium of medical centers dedicated to bringing clinical trials to patients with all types of cancer.
Our staff includes a team of physicians, scientists, nurses, pharmacists, and social workers with expertise in the use of immunotherapy in patients with cancer.
Patients ordinarily need to meet certain medical requirements before enrolling in a clinical trial.
You or your medical oncologist can contact us to learn about eligibility requirements.
Participation is voluntary and you may withdraw at any time.
A list of our active trials follows, but we recommend calling to get the most up to date information on our clinical trials program.
For more information regarding participation in one of our trials please contact Gail DeRaffele, RN, Clinical Coordinator at 212.342.0232 or gd2023@columbia.edu.
Melanoma Trials
- IntraLesional rF-B7.1 Versus rF-TRICOM in the Treatment of Metastatic Cancer
- A Phase III Multi-Institutional Randomization Study of Immunization with the gap 100:209:-217 (210M) Peptide Followed by High Dose IL-2 Versus High Dose IL-2 Alone in Patients with Metastatic Melanoma
- The Effect of High Dose Interleukin-2 Therapy on Peripheral Blood CD4+ CD25+ Regulatory T Cells in Metastatic Cancer Patients.
- A Randomized, Two-Stage, Multicenter study Comparing MDX-010 in Combination with a Melanoma Vaccine, and Melanoma Vaccine Alone in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
- A Randomized Double Blind Multi-centered phase II fixed dose study of multiple doses of ipilimumab (MDX10) monotherapy in patients with previously treated unresectable stage III or IV melanoma
- A Phase II Study of the Efficacy safety and immunogenicity of Oncovex in patients with stage IIIc and IV malignant melanoma
- A phase II trial of sequential high dose interleukin 2 followed by temozolomide and GM-CSF in metastatic melanoma
Renal Cell Trials
- A Preliminary Study of the Safety, Immunogenicity and Clinical Efficacy of TroVax given in conjunction with Interleukin-2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer
Links
|
